Asked by: Lord Bishop of Southwark (Bishops - Bishops)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what progress they have made in allocating the Market Sustainability and Improvement Fund 2023 to 2024 for adult social care; and what are their plans for allocation in the financial year 2024–25.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The Market Sustainability and Improvement Fund (MSIF) gives an overall profile of almost £2 billion over two years. Local authorities can choose to use the funding to increase fee rates paid to adult social care providers, increase adult social care workforce capacity and retention, and reduce adult social care waiting times.
In 2023/34, a total of £927 million was made available to local authorities via MSIF, with a further £1.05 billion being made available in 2024/25. The funding has been distributed using the adult social care relative needs formula. Full local authority allocations for 2024/25 are available in the Market Sustainability and Improvement Fund Grant Determination 2024 to 2025 on GOV.UK in an online-only format.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential merits of a full advertising ban on companies promoting vaping products.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
The health advice is clear, if you don’t smoke, don’t vape and children should never vape. Advertising of vapes is already restricted by existing regulations. This includes a ban on advertising on television and radio, and through internet advertising, or commercial email. However, products can still be promoted elsewhere, such as on digital billboards.
Whilst we are not currently planning on making any further changes to the rules regarding vape advertising, we are taking action to protect children from the harms of vaping by taking new regulation making powers that can be used to limit vape flavours, how vapes are packaged, and where and how they can be displayed in retail settings. Collectively, these actions will reduce the appeal and accessibility of vapes to children, whilst ensuring vapes remain an effective smoking cessation tool for adult smokers.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she has made an assessment of the risk of people moving from non-nicotine to nicotine vapes.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Our health advice regarding vapes covers both non-nicotine as well as nicotine vapes, that while vaping can play a useful role in helping adult smokers to quit, non-smokers and children should never vape. The long-term health impacts of vaping are unknown, and the nicotine contained within nicotine vapes can be highly addictive.
We recognise the risk of non-nicotine vapes being used as a gateway to nicotine vapes by children. That is why the Tobacco and Vapes Bill includes new regulation making powers that will cover all vapes, nicotine as well as non-nicotine, to reduce their appeal and availability to children and non-smokers.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent assessment she has made of the effectiveness of the BALM programme.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
NHS England is currently undertaking a review of how health and wellbeing support could be delivered more effectively. As part of this review, the team will: assess NHS England’s current contracts; work with integrated care boards, National Health Service trusts, and primary care organisations to understand the scale and impact of locally provided provision; and work with system partners and stakeholders including royal colleges, the voluntary sector, and the independent sector to understand how demand for these services has changed over recent years.
Asked by: John Hayes (Conservative - South Holland and The Deepings)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much funding her Department has given to Stonewall since 2019.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Our financial records show a total sum of £6,000 paid to Stonewall between the years 2019 to 2020, as part of the Diversity Champions annual membership. This is broken down into £3,000 between 1 January 2019 and 31 December 2019, and £3,000 between 1 January 2020 and 31 December 2020. As of February 2021, the Department’s membership with Stonewall lapsed, with no further payments made from 2021 to date.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential merits of banning the use of vapes in (a) public spaces, (b) bars and (c) vehicles with child passengers.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Vaping can be an effective tool for adult smokers to quit smoking. However, the health advice is clear, if you don’t smoke, don’t vape, and children should never vape. This is why the Tobacco and Vapes Bill will give us powers to crack down on child friendly flavours and packaging, and to change the way vapes are displayed in shops, measures on which we will shortly consult.
Inhaling anything other than fresh air may have long term health effects. Evidence on the harm from exposure to second-hand tobacco smoke is well established and because of its carcinogenic content there is no safe level of exposure. Breathing in other people’s tobacco smoke is known to cause a range of health issues. However, there is currently no evidence to suggest that second-hand vapour causes wider health harms in the way tobacco smoke does. Therefore, the Government has no plans to introduce restrictions on where people can vape.
However, many public venues and spaces have their own policies on vaping. For example, most hospitals and public transport have banned vaping. Employers or operators of indoor spaces would be within their rights to implement policies banning the use of vapes in their premises and many do so.
Asked by: Henry Smith (Conservative - Crawley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what information her Department holds on the number of non-invasive pre-natal tests branded as NIFTY and manufactured by BGI Group have been sold in the UK.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department and NHS England do not hold information on the sales within the United Kingdom of the non-invasive pre-natal tests branded as NIFTY, manufactured by BGI Group. The NHS Supply Chain, who manage the sourcing, delivery, and supply of healthcare products, services, and food for National Health Service trusts and healthcare organisations across England, develop procurement frameworks which enable NHS organisations to buy goods and services from suppliers. NHS Supply Chain has confirmed that non-invasive pre-natal tests branded as NIFTY and manufactured by BGI Group, are not on their procurement framework.
Asked by: Jim Shannon (Democratic Unionist Party - Strangford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to (a) trial and (b) roll-out early cancer screening.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
In England, early cancer screening is already in place for cervical, breast, and bowel cancer. The UK National Screening Committee (UK NSC) does not currently recommend screening for prostate cancer due to the inaccuracy of the current best test, called Prostate Specific Antigen. We are providing £16 million of funding to Prostate Cancer UK's £42 million trial, which is aimed at helping us find a way of catching prostate cancer in men as early as possible. The UK NSC is also commissioning evidence for six possible approaches to targeted prostate screening for those at higher risk. The UK NSC will publish its recommendations when complete.
NHS England is responsible for the running of the Targeted Lung Health Check Programme, and its conversion to a nationally rolled out NHS Targeted Lung Cancer Screening Programme by 2030.
Asked by: Dean Russell (Conservative - Watford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what support exists for those with (a) Huntington’s disease and (b) other complex neurological conditions.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Integrated care boards (ICBs) are responsible for commissioning most services for people with neurological conditions, including those with Huntington’s disease. At a national level, NHS England commissions the specialised elements of neurological care that patients may receive from 27 specialised neurological treatment centres across England. NHS England’s RightCare toolkit and Getting It Right First Time programme aim to improve care for people with neurological conditions, by reducing variation and delivering care more equitably across England.
New optimal clinical pathways for a range of neurological conditions were developed by the National Neurosciences Advisory Group, which ceased operation in 2022. These pathways set out what good treatment, care, and support should look like across a range of neurological conditions. They also help to guide and facilitate the commissioning of high-quality, effective neurology services by ICBs. The optimal clinical pathway for movement disorders outlines the care pathway that patients with Huntington’s disease should receive. Further information on the optimal clinical pathways are available at the following link:
https://www.nnag.org.uk/optimum-clinical-pathways
The Department funds research on neurological conditions through the National Institute for Health and Care Research (NIHR), and between 2018/19 and 2022/23, the Department spent £272.1 million on research into neurological conditions. This covers research into conditions such as Huntington’s disease, Parkinson’s disease, epilepsy, and multiple sclerosis. In 2022/23, the most recent year for which we have data, the Department, via the NIHR, spent £65.3 million on research into neurological conditions.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she has made an assessment of the implications for her policies of research by Professor Martin Schwendler and Dr Chiara Herzog on changes to epithelial cells caused by vaping.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Vaping is never recommended for children, and carries the potential harms of future addiction while their lungs and brains are still developing. The health advice is clear, vapes can be an effective tool to help smokers quit, but young people and those who have never smoked should not vape, or be encouraged to vape.
As stated by Cancer Research UK, this study contributes to our understanding of e-cigarettes, also known as vapes, but does not show that e-cigarettes cause cancer. Decades of research has proven the link between smoking and cancer, and studies have so far shown that e-cigarettes are far less harmful than smoking, and can help people quit. This paper does, however, highlight that vapes are not risk-free, and so we need additional studies to uncover their potential longer-term impacts on human health.